Timed walking speed in progressive multiple sclerosis: molecular mechanisms & dependencies

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

Human evidence only

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

The larger phase 2 trial found no improvement in timed walking speed or other reported clinical outcomes at 24 months.
Lipoic acid → Timed walking speed in progressive multiple sclerosis source_derived_draftungraded
Experimental context and source evidence
evidence_span
{"source_cache": "artifacts/ala-research/41397213.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "7fbea8d712bb6bea0dd8b7cfde3133b06d70a6eb881917767f4385f61c8d27ba", "start_char": 0, "end_char": 3010, "text_sha256": "7fbea8d712bb6bea0dd8b7cfde3133b06d70a6eb881917767f4385f61c8d27ba"}
experimental_model
Phase 2 randomized placebo-controlled progressive-MS trial; online December 2025, 2026 issue
exposure
Oral ALA 1200 mg/day for 24 months
limitations
Primary timed-walking result was null; imaging interpretation complicated by T2 lesion volume and differential discontinuation.
nutrient_topic
Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect. · Lipoic acid
organism
Human
plain_language
The later study did not establish functional benefit.
primary_references
[ala-p41397213] Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial. (2026). https://pubmed.ncbi.nlm.nih.gov/41397213/ DOI: 10.1212/wnl.0000000000214454
tissue_or_cell_type
115 participants, 54 ALA and 61 placebo
Alpha-lipoic acid: cofactor assembly, redox signaling and nutrient interactions (2026-09-17) · lines 1261–1272
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Phase 2 randomized placebo-controlled progressive-MS trial; online December 2025, 2026 issue · source_derived_draft · unverified_draft
### ala-ms-phase2-walking-null The larger phase 2 trial found no improvement in timed walking speed or other reported clinical outcomes at 24 months. Condition category: normal nutrient_topic: Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect. plain_language: The later study did not establish functional benefit. organism: Human tissue_or_cell_type: 115 participants, 54 ALA and 61 placebo experimental_model: Phase 2 randomized placebo-controlled progressive-MS trial; online December 2025, 2026 issue limitations: Primary timed-walking result was null; imaging interpretation complicated by T2 lesion volume and differential discontinuation. exposure: Oral ALA 1200 mg/day for 24 months evidence_span: {"source_cache": "artifacts/ala-research/41397213.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "7fbea8d712bb6bea0dd8b7cfde3133b06d70a6eb881917767f4385f61c8d27ba", "start_char": 0, "end_char": 3010, "text_sha256": "7fbea8d712bb6bea0dd8b7cfde3133b06d70a6eb881917767f4385f61c8d27ba"} [ala-p41397213] Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial. (2026). https://pubmed.ncbi.nlm.nih.gov/41397213/ DOI: 10.1212/wnl.0000000000214454
Complete structured claim and evidence
The pilot’s timed-walking comparison did not reach conventional statistical significance (P=0.06).
Lipoic acid → Timed walking speed in progressive multiple sclerosis source_derived_draftungraded
Experimental context and source evidence
evidence_span
{"source_cache": "artifacts/ala-research/28680916.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "fc584ca455d8a40e4ce91513974752b282425a74267d5b1d45db6275a51c2f5d", "start_char": 0, "end_char": 1904, "text_sha256": "fc584ca455d8a40e4ce91513974752b282425a74267d5b1d45db6275a51c2f5d"}
experimental_model
Two-year randomized placebo-controlled progressive-MS pilot
exposure
Oral lipoic acid 1200 mg/day
limitations
Small imaging-focused trial; brain volume is a surrogate and the walking comparison was not statistically significant.
nutrient_topic
Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect. · Lipoic acid
organism
Human
plain_language
A favorable scan result did not establish improved walking.
primary_references
[ala-p28680916] Lipoic acid in secondary progressive MS: A randomized controlled pilot trial. (2017). https://pubmed.ncbi.nlm.nih.gov/28680916/ DOI: 10.1212/nxi.0000000000000374
tissue_or_cell_type
51 randomized participants with secondary progressive multiple sclerosis
Alpha-lipoic acid: cofactor assembly, redox signaling and nutrient interactions (2026-09-17) · lines 1248–1259
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Two-year randomized placebo-controlled progressive-MS pilot · source_derived_draft · unverified_draft
### ala-ms-pilot-walking-null The pilot’s timed-walking comparison did not reach conventional statistical significance (P=0.06). Condition category: normal nutrient_topic: Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect. plain_language: A favorable scan result did not establish improved walking. organism: Human tissue_or_cell_type: 51 randomized participants with secondary progressive multiple sclerosis experimental_model: Two-year randomized placebo-controlled progressive-MS pilot limitations: Small imaging-focused trial; brain volume is a surrogate and the walking comparison was not statistically significant. exposure: Oral lipoic acid 1200 mg/day evidence_span: {"source_cache": "artifacts/ala-research/28680916.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "fc584ca455d8a40e4ce91513974752b282425a74267d5b1d45db6275a51c2f5d", "start_char": 0, "end_char": 1904, "text_sha256": "fc584ca455d8a40e4ce91513974752b282425a74267d5b1d45db6275a51c2f5d"} [ala-p28680916] Lipoic acid in secondary progressive MS: A randomized controlled pilot trial. (2017). https://pubmed.ncbi.nlm.nih.gov/28680916/ DOI: 10.1212/nxi.0000000000000374
Complete structured claim and evidence

The events it takes part in

A mechanism often involves more than two components. These are the full events, with every participant and its role.

Situations it appears in

Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

Open hypotheses

Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.

This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

Timed walking speed in progressive multiple sclerosis